Corporate Information
Search the website.
Tell a friend.
Bookmark this website.
Corporate Information Services Testimonials

Email This Print This Board Of Directors

Dr. Ho Choon Hou

Dr. Ho Choon Hou

Singaporean, aged 41, was appointed as Non-Independent Non-Executive Chairman of StemLife ("the Company") on 9 December 2013. He is also the Chairman of the Remuneration Committee and member of the Nomination Committee of the Company.
Toggle Profile

Dr. Ho graduated with a Bachelor of Medicine & Bachelor of Surgery (Honours) from The University of Sheffield, as well as a Master of Medicine (Surgery) from the National University of Singapore. He also obtained his Master of Business Administration (Honours) from The University of Chicago (The Graduate School of Business).

Dr. Ho is a medical doctor by qualification and has vast experience in the financial and healthcare industries. He was a Registrar in the Department of General Surgery at the Tan Tock Seng hospital. He was also the Project Office Head and subsequently Deputy Director at the National Healthcare Group where he was involved in directing special projects and investments and held general management responsibilities.

He is the Non-Executive Chairman of Cordlife Group Limited, a company listed on the Stock Exchange of Singapore. Currently, Dr. Ho is an Executive Director at Southern Capital Group Limited, a private equity fund management firm since 2007. He is also an Independent Director of Advanced Holdings Ltd. and Mclean Technologies Bhd.

Dr. Ho does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any. Dr. Ho has attended one (1) out of the five (5) Board Meetings of the Company held during the financial year.

Dato' Low Su-Shing, Sharon

Dato' Low Su-Shing, Sharon

Singaporean, age 38, was appointed as Executive Director of the Company on 13 December 2001.
Toggle Profile

Dato' Low started StemLife in 2001 and is currently its Managing Director. She is responsible for the management, strategies and business direction of StemLife. She is also the co-founder and Chairperson of the Asia Pacific Cord Blood Bank Consortium (APCBBC). She is an invited scientific advisory panel member for the US-based Parent's Guide to Cord Blood Foundation and Malaysian-based biotechnology education group MABIC. Prior to StemLife, Dato' Low was a research scientist at the Institute of Molecular Agrobiology affiliated to the National University of Singapore. She holds a Bachelor of Science (Hons) in Biochemistry from the University of Bristol, UK.

Dato' Low does not sit on the board of any other public listed company.

Dato' Low does not have any family relationship with any other directors or major shareholders of the Company. She has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any.

Dato' Low has attended four (4) out of the five (5) Board Meetings of the Company held during the financial year.

Dato' Lim Oi Wah, Christina

Dato' Lim Oi Wah, Christina

Malaysian, age 60, was appointed as Executive Director of the Company on 13 December 2001.
Toggle Profile

She is a co-founder of StemLife and is currently its Deputy Managing Director. She is responsible for the management of the operations of StemLife. She has extensive experience in business development, financial planning and advisory management.

Dato' Lim does not sit on the board of any other public listed company.

Dato' Lim does not have any family relationship with any other directors or major shareholders of the Company except for Mr. Lim Jit Soon who is her brother and an Executive Director of the Company. She has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any.

Dato' Lim attended all five (5) Board Meetings of the Company held during the financial year.

Yap Yu Ming

Yap Yu Ming

Malaysian, age 45, was appointed as Independent Non-Executive Director of the Company on 16 February 2011. She is also the Chairperson of the Audit Committee and a member of the Nomination Committee of the Company.
Toggle Profile

Ms. Yap is a Certified Practising Accountant of the Australian Society of Certified Practising Accountants (ASCPA), and is a registered Chartered Accountant with Malaysian Institute of Accountants (MIA). In 1990, she graduated from University of Newcastle, Australia, with a Bachelor of Commerce majoring in Accounting, and later on obtained a Master of Business Administration (MBA) from University of Malaya in 2000. She has 20 years of experience in finance and administration in various industries, mostly in property development and management.

Ms. Yap does not sit on the board of any other public listed company.

Ms. Yap does not have any family relationship with any other directors or major shareholders of the Company. She has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any.

Ms. Yap attended all five (5) Board Meetings of the Company held during the financial year.

YM Dr. Raja Abdul Malek bin Raja Jallaludin

YM Dr. Raja Abdul Malek bin Raja Jallaludin

Malaysian, age 68, was appointed as Non-Independent Non- Executive Director of the Company on 26th September 2012
Toggle Profile

Dr. Raja Abdul Malek graduated from the University of Malaya in 1972. He then worked at the Kuala Lumpur General Hospital as well as the Faculty of Medicine at University Kebangsaan Malaysia (UKM). In late 1975, he went into private medical practice and was a senior partner of Drs. Catterall, Khoo, Raja Malek & Partners one of the most senior medical group practices, overseeing local and expatriate healthcare in the Klang Valley.

Dr. Raja Abdul Malek also has vast experience in the pharmaceutical world and has actively been involved since 1984. However, it was in 2003 that Dr. Raja Abdul Malek joined HOE Pharmaceuticals/HOE Pharma Holdings (a fully owned subsidiary of TAISHO Pharmaceutical Company Ltd., Japan) as Director for Medical and Scientific Affairs, a position that he holds to this day.

His other directorships in public and private companies include ABB Trustee Berhad and AFFIN Bank Berhad. He has more than 20 years of varied experience associated with the medical, sports, banking and pharmaceutical industries.

Dr. Raja Abdul Malek does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any.

Dr. Raja Abdul Malek has attended four (4) out of the five (5) Board Meetings of the Company held during the financial year.

Dato' Mark William Ling Lee Meng

Dato' Mark William Ling Lee Meng

Malaysian, aged 51, was appointed as Independent Non-Executive Director of the Company on 9 December 2013. He is also the Chairman of the Nomination Committee and a member of the Audit Committee and Remuneration Committee of the Company.
Toggle Profile

Upon completing his high school education at The Southport School in Australia, Dato' Mark started his career in the family business at Kong Ming Bank Berhad. He was appointed as Marketing Director where he was involved in project finance transactions in a number of industry sectors. Dato' Mark left the banking industry and focused on the development of green field power projects in the Asia Pacific region.

Dato' Mark was appointed as Strategic Planning Advisor by Powergen International and was responsible to create proprietary deal flow to develop power project portfolios in the Asia Pacific region. He was then set up a private equity firm specialising in the energy sectors and has been involved with strategic investments focused primarily in the emerging economies in the Asia Pacific and Africa regions.

Dato' Mark is currently an Independent Non-Executive Director of MClean Technologies Berhad and sits as the Chairman of the Nomination Committee, Remuneration Committee and Audit Committee of MClean.

Dato' Mark does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any. Dato' Mark has attended one (1) out of the five (5) Board Meetings of the Company held during the financial year.

Yee Pinh Jeremy

Yee Pinh Jeremy

Singaporean, aged 44, was appointed as Non-Independent Non- Executive Director of the Company on 9 December 2013. He is also a member of the Audit Committee and Remuneration Committee of the Company.
Toggle Profile

Mr. Yee obtained his Bachelor of Arts in Economics and Social Studies from Victoria University of Manchester. He also holds a Bachelor of Commerce (Prof Accounting) from University of Sydney and a Master of Commerce from Murdoch University. In addition, he also holds a Master of Business Administration from Nanyang Technological University (2011) and University of Chicago (2012).

As Executive Director and Chief Executive Officer of Cordlife Group Limited, Mr. Yee is responsible for identifying and implementing company-wide business growth strategies and organisational structures, and directly oversees all aspects of the Group's growth and operating functions. He was previously Director of Corporate Development and later Chief Operating Officer of Cordlife Group Limited, where he was responsible for its overall corporate development activities. His career began in 1994, where he worked with Malayan Bank Berhad. He then joined Singapore Airlines as a Cadet Pilot before moving on to jobs in the credit and finance industries with American Express, KPMG LLP and UOB Bank Limited.

Mr. Yee does not sit on the board of any other public listed company.

Mr. Yee does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any. Mr. Yee has attended one (1) out of the five (5) Board Meetings of the Company held during the financial year.

Sahba Phillipe Christiane Saint-Claire

Sahba Phillipe Christiane Saint-Claire

Australian, age 49, was appointed as Independent Non-Executive Director of the Company on 18 March 2014.
Toggle Profile

Mr. Sahba Saint-Claire is an experienced executive with over 25 years of experience gained from working in senior regional and global roles with leading financial institutions. He has worked with Standard Chartered Bank, Development Bank of Singapore, JP Morgan Investment Bank and Westpac Bank - mainly in backoffice systems, technology applications and infrastructure on CRM, equities, derivatives, research and the financial markets.

He started his career with Westpac as a systems analyst, later as a consultant and employment with the aforesaid financial institutions before setting up his own company named AIAS Solutions in July 2013 in Singapore, providing advice to financial institutions and their software and service providers.

Mr. Sahba Saint-Claire holds a Bachelor of Science degree in Pure Mathematics and Computer Science from the University of Sydney in Australia.

Mr. Sahba Saint-Claire does not sit on the board of any other public listed company.

Mr. Sahba Saint-Claire does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any.

Jonathan Liau Yen San

Jonathan Liau Yen San

Singaporean, age 35, was appointed as Alternate Director to Mr. Yee Pinh Jeremy, Non-Independent Non-Executive Director on 9 December 2013.
Toggle Profile

Mr. Liau obtained his Master of Biochemical Engineering with Bioprocess Management from University College London, United Kingdom in 2004. In addition to being awarded first class honours and Dean's list, he was awarded the Lonza Biologics Prize for best bioprocess studies and the Kitson Prize for outstanding graduating student. Mr. Liau also obtained the Master of Business Administration from University of Chicago, Booth School of Business.

Mr. Liau started his career at LCL as Business and Technology Development Executive. He was then promoted to Business and Technology Development Manager and later took on the roles of Head of Business Development and Corporate Development Director before becoming LCL's Chief Operating Officer in 2011. Following the acquisition of LCL's business in India, Indonesia and Philippines, Mr. Liau was appointed as Senior Director of Cordlife Group Limited and is responsible for all operational functions and business units within India, Indonesia and Philippines.

Mr. Liau does not sit on the board of any other public listed company.

Mr. Liau does not have any family relationship with any other directors or major shareholders of the Company. He has no conflict of interest with the Company and has not been convicted of any offences within the past ten (10) years, other than minor traffic offences, if any. Mr. Liau has attended one (1) out of the five (5) Board Meetings of the Company held during the financial year.